182 related articles for article (PubMed ID: 28207808)
21. Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation.
Kaloyannidis P; Voutiadou G; Baltadakis I; Tsirigotis P; Spyridonidis A; Repousis P; Balta A; Tsimberis S; Karakasis D; Sakellari I; Dervenoulas I; Harhalakis N; Anagnostopoulos A
Biol Blood Marrow Transplant; 2012 Mar; 18(3):451-7. PubMed ID: 21803018
[TBL] [Abstract][Full Text] [Related]
22. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes.
Frankovich J; Donaldson SS; Lee Y; Wong RM; Amylon M; Verneris MR
Biol Blood Marrow Transplant; 2001; 7(1):49-57. PubMed ID: 11215699
[TBL] [Abstract][Full Text] [Related]
23. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
24. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
[TBL] [Abstract][Full Text] [Related]
25. Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.
Shindiapina P; Pietrzak M; Seweryn M; McLaughlin E; Zhang X; Makowski M; Ahmed EH; Schlotter S; Pearson R; Kitzler R; Mozhenkova A; Le-Rademacher J; Little RF; Akpek G; Ayala E; Devine SM; Kaplan LD; Noy A; Popat UR; Hsu JW; Morris LE; Mendizabal AM; Krishnan A; Wachsman W; Williams N; Sharma N; Hofmeister CC; Forman SJ; Navarro WH; Alvarnas JC; Ambinder RF; Lozanski G; Baiocchi RA
Front Immunol; 2021; 12():700045. PubMed ID: 34539628
[TBL] [Abstract][Full Text] [Related]
26. Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Seshadri T; Pintilie M; Kuruvilla J; Keating A; Tsang R; Zadeh S; Crump M
Leuk Lymphoma; 2009 Mar; 50(3):380-6. PubMed ID: 19347727
[TBL] [Abstract][Full Text] [Related]
27. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma.
Traweek ST; Slovak ML; Nademanee AP; Brynes RK; Niland JC; Forman SJ
Blood; 1994 Aug; 84(3):957-63. PubMed ID: 8043877
[TBL] [Abstract][Full Text] [Related]
28. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
[TBL] [Abstract][Full Text] [Related]
29. High Proliferating Regulatory T Cells Post-Transplantation Are Associated with Poor Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation.
Sumransub N; Cao Q; Wangen R; Brunstein C; Miller JS; Bachanova V
Transplant Cell Ther; 2022 Apr; 28(4):184.e1-184.e8. PubMed ID: 35081473
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
Sobecks RM; Le Beau MM; Anastasi J; Williams SF
Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
[TBL] [Abstract][Full Text] [Related]
31. A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma.
Wang L; Wei Q; Shi Q; Guo Z; Qiao Y; Spitz MR
Carcinogenesis; 2007 Jul; 28(7):1430-6. PubMed ID: 17341660
[TBL] [Abstract][Full Text] [Related]
32. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
33. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
Gibson CJ; Lindsley RC; Tchekmedyian V; Mar BG; Shi J; Jaiswal S; Bosworth A; Francisco L; He J; Bansal A; Morgan EA; Lacasce AS; Freedman AS; Fisher DC; Jacobsen E; Armand P; Alyea EP; Koreth J; Ho V; Soiffer RJ; Antin JH; Ritz J; Nikiforow S; Forman SJ; Michor F; Neuberg D; Bhatia R; Bhatia S; Ebert BL
J Clin Oncol; 2017 May; 35(14):1598-1605. PubMed ID: 28068180
[TBL] [Abstract][Full Text] [Related]
34. Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature.
Keung YK; Beaty MW; Pettenati M; Levitan D; Hurd DD
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):129-33. PubMed ID: 20371446
[TBL] [Abstract][Full Text] [Related]
35. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ
Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261
[TBL] [Abstract][Full Text] [Related]
36. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.
Satwani P; Jin Z; Martin PL; Bhatia M; Garvin JH; George D; Chaudhury S; Talano J; Morris E; Harrison L; Sosna J; Peterson M; Militano O; Foley S; Kurtzberg J; Cairo MS
Leukemia; 2015 Feb; 29(2):448-55. PubMed ID: 24938649
[TBL] [Abstract][Full Text] [Related]
37. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
38. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Krishnan A; Bhatia S; Slovak ML; Arber DA; Niland JC; Nademanee A; Fung H; Bhatia R; Kashyap A; Molina A; O'Donnell MR; Parker PA; Sniecinski I; Snyder DS; Spielberger R; Stein A; Forman SJ
Blood; 2000 Mar; 95(5):1588-93. PubMed ID: 10688812
[TBL] [Abstract][Full Text] [Related]
39. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
